Trial · NCT00356278
D-cycloserine and Virtual Reality Exposure to Treat Iraq War Veterans With PTSD
NCT00356278, Phase 2, Phase 3, Completed, Emory University; results first posted 2014-11-19
3 sourcestrials-2026-11-12-0.5.0
Download JSON
Cite this record
ConductScience Library. D-cycloserine and Virtual Reality Exposure to Treat Iraq War Veterans With PTSD. Trials, record NCT00356278. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT00356278
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- D-cycloserine and Virtual Reality Exposure to Treat Iraq War Veterans With PTSD
- NCT number
- NCT00356278
- Status
- Completed
- Phases
- Phase 2, Phase 3
- Enrollment
- 156 participants, actual
- Lead sponsor
- Emory University
- Conditions
- Stress Disorder, Post Traumatic
- Interventions
- D-Cycloserine, Alprazolam, Virtual Reality Exposure Therapy, Placebo
- First posted
- 2006-07-25
- Last updated
- 2016-01-08
- Results first posted
- 2014-11-19
- Limitations and caveats
The study had a high dropout rate. 31 participants dropped out before the first treatment session. Although disheartening, the dropout rate is similar to rates in other studies with veterans and active duty personnel.
Source ClinicalTrials.gov
Registered outcomes10
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Clinician-Administered PTSD Scale (CAPS) | Baseline | Scores may range from 0 (no symptoms) to 136 (severe symptoms). The score is based on the first 17 CAPS items administered. |
| Primary | Clinician-Administered PTSD Scale (CAPS) | Posttreatment, 8 weeks | Scores may range from 0 (no symptoms) to 136 (severe symptoms). The score is based on the first 17 CAPS items administered. |
| Primary | Clinician-Administered PTSD Scale (CAPS) | Month 3 | Scores may range from 0 (no symptoms) to 136 (severe symptoms). The score is based on the first 17 CAPS items administered. |
| Primary | Clinician-Administered PTSD Scale (CAPS) | Month 6 | Scores may range from 0 (no symptoms) to 136 (severe symptoms). The score is based on the first 17 CAPS items administered. |
| Primary | Clinician-Administered PTSD Scale (CAPS) | Month 12 | Scores may range from 0 (no symptoms) to 136 (severe symptoms). The score is based on the first 17 CAPS items administered. |
| Secondary | PTSD Symptom Scale Self-Report | Baseline | PTSD Symptom Scale - Self-Report Version (PSS-SR) is a 17-item self-reported questionnaire to assess symptoms of PTSD. Each of the 17 items describe PTSD symptoms which respondents rate in terms of their frequency or severity using a Likert-type scale ranging from 0 (not at all or only one time) to 3 (almost always or five or more times per week). Ratings on items are summed to create three subscales, including re-experiencing, avoidance, and arousal, as well as a total score (that ranges from 0 to 51). The total score higher than 13 indicates on likelihood of PTSD. |
| Secondary | PTSD Symptom Scale Self-Report | Posttreatment, 8 weeks | PTSD Symptom Scale - Self-Report Version (PSS-SR) is a 17-item self-reported questionnaire to assess symptoms of PTSD. Each of the 17 items describe PTSD symptoms which respondents rate in terms of their frequency or severity using a Likert-type scale ranging from 0 (not at all or only one time) to 3 (almost always or five or more times per week). Ratings on items are summed to create three subscales, including re-experiencing, avoidance, and arousal, as well as a total score (that ranges from 0 to 51). The total score higher than 13 indicates on likelihood of PTSD. |
| Secondary | PTSD Symptom Scale Self-Report | Month 3 | PTSD Symptom Scale - Self-Report Version (PSS-SR) is a 17-item self-reported questionnaire to assess symptoms of PTSD. Each of the 17 items describe PTSD symptoms which respondents rate in terms of their frequency or severity using a Likert-type scale ranging from 0 (not at all or only one time) to 3 (almost always or five or more times per week). Ratings on items are summed to create three subscales, including re-experiencing, avoidance, and arousal, as well as a total score (that ranges from 0 to 51). The total score higher than 13 indicates on likelihood of PTSD. |
| Secondary | PTSD Symptom Scale Self-Report | Month 6 | PTSD Symptom Scale - Self-Report Version (PSS-SR) is a 17-item self-reported questionnaire to assess symptoms of PTSD. Each of the 17 items describe PTSD symptoms which respondents rate in terms of their frequency or severity using a Likert-type scale ranging from 0 (not at all or only one time) to 3 (almost always or five or more times per week). Ratings on items are summed to create three subscales, including re-experiencing, avoidance, and arousal, as well as a total score (that ranges from 0 to 51). The total score higher than 13 indicates on likelihood of PTSD. |
| Secondary | PTSD Symptom Scale Self-Report | Month 12 | PTSD Symptom Scale - Self-Report Version (PSS-SR) is a 17-item self-reported questionnaire to assess symptoms of PTSD. Each of the 17 items describe PTSD symptoms which respondents rate in terms of their frequency or severity using a Likert-type scale ranging from 0 (not at all or only one time) to 3 (almost always or five or more times per week). Ratings on items are summed to create three subscales, including re-experiencing, avoidance, and arousal, as well as a total score (that ranges from 0 to 51). The total score higher than 13 indicates on likelihood of PTSD. |
Source ClinicalTrials.gov
Outcomes10
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
| Type | Outcome | Time frame | Population | Units | Measured as |
|---|---|---|---|---|---|
| PRIMARY | Clinician-Administered PTSD Scale (CAPS) | Baseline | Intent to Treat Analyses using all available information with Full Information Maximum Likelihood Estimation (FIML)to handle missing data | units on a scale | MEAN |
| SECONDARY | PTSD Symptom Scale Self-Report | Baseline | Intent to Treat Analyses using all available information with Full Information Maximum Likelihood Estimation (FIML)to handle missing data | units on a scale | MEAN |
| PRIMARY | Clinician-Administered PTSD Scale (CAPS) | Posttreatment, 8 weeks | Intent to Treat Analyses using all available information with Full Information Maximum Likelihood Estimation (FIML)to handle missing data | units on a scale | MEAN |
| PRIMARY | Clinician-Administered PTSD Scale (CAPS) | Month 3 | Intent to Treat Analyses using all available information with Full Information Maximum Likelihood Estimation (FIML)to handle missing data | units on a scale | MEAN |
| PRIMARY | Clinician-Administered PTSD Scale (CAPS) | Month 6 | Intent to Treat Analyses using all available information with Full Information Maximum Likelihood Estimation (FIML)to handle missing data | units on a scale | MEAN |
| PRIMARY | Clinician-Administered PTSD Scale (CAPS) | Month 12 | Intent to Treat Analyses using all available information with Full Information Maximum Likelihood Estimation (FIML)to handle missing data | units on a scale | MEAN |
| SECONDARY | PTSD Symptom Scale Self-Report | Posttreatment, 8 weeks | Intent to Treat Analyses using all available information with Full Information Maximum Likelihood Estimation (FIML)to handle missing data | units on a scale | MEAN |
| SECONDARY | PTSD Symptom Scale Self-Report | Month 3 | Intent to Treat Analyses using all available information with Full Information Maximum Likelihood Estimation (FIML)to handle missing data | units on a scale | MEAN |
| SECONDARY | PTSD Symptom Scale Self-Report | Month 6 | Intent to Treat Analyses using all available information with Full Information Maximum Likelihood Estimation (FIML)to handle missing data | units on a scale | MEAN |
| SECONDARY | PTSD Symptom Scale Self-Report | Month 12 | Intent to Treat Analyses using all available information with Full Information Maximum Likelihood Estimation (FIML)to handle missing data | units on a scale | MEAN |
Source ClinicalTrials.gov
Results by group30
Each measurement the trial posted, group by group, in the words and numbers it posted.
| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Clinician-Administered PTSD Scale (CAPS) | VRE Therapy and D-cycloserine | 85.3 | 95% Confidence Interval 79.3 to 91.9 | units on a scale | |
| Clinician-Administered PTSD Scale (CAPS) | VRE Therapy and Alprazolam | 88 | 95% Confidence Interval 82.3 to 93.6 | units on a scale | |
| Clinician-Administered PTSD Scale (CAPS) | VRE Therapy and Placebo | 82.6 | 95% Confidence Interval 75.8 to 89.4 | units on a scale | |
| PTSD Symptom Scale Self-Report | VRE Therapy and D-cycloserine | 32.9 | 95% Confidence Interval 29.7 to 36.2 | units on a scale | |
| PTSD Symptom Scale Self-Report | VRE Therapy and Alprazolam | 32.4 | 95% Confidence Interval 26.0 to 38.9 | units on a scale | |
| PTSD Symptom Scale Self-Report | VRE Therapy and Placebo | 32.4 | 95% Confidence Interval 29.1 to 35.7 | units on a scale | |
| Clinician-Administered PTSD Scale (CAPS) | VRE Therapy and D-cycloserine | 65.9 | 95% Confidence Interval 60.2 to 71.6 | units on a scale | |
| Clinician-Administered PTSD Scale (CAPS) | VRE Therapy and Alprazolam | 69.6 | 95% Confidence Interval 63.8 to 75.4 | units on a scale | |
| Clinician-Administered PTSD Scale (CAPS) | VRE Therapy and Placebo | 63.8 | 95% Confidence Interval 56.7 to 70.9 | units on a scale | |
| Clinician-Administered PTSD Scale (CAPS) | VRE Therapy and D-cycloserine | 60.3 | 95% Confidence Interval 54.4 to 66.2 | units on a scale |
1 to 10 of 30Source ClinicalTrials.gov
See all 30 results by groupParticipant flow9
How many started, completed or left each group, period by period.
| Period | Milestone | Group | Participants | Units counted |
|---|---|---|---|---|
| Overall Study | STARTED | VRE Therapy and D-cycloserine | 53 | |
| Overall Study | STARTED | VRE Therapy and Alprazolam | 50 | |
| Overall Study | STARTED | VRE Therapy and Placebo | 53 | |
| Overall Study | COMPLETED | VRE Therapy and D-cycloserine | 28 | |
| Overall Study | COMPLETED | VRE Therapy and Alprazolam | 35 | |
| Overall Study | COMPLETED | VRE Therapy and Placebo | 34 | |
| Overall Study | NOT COMPLETED | VRE Therapy and D-cycloserine | 25 | |
| Overall Study | NOT COMPLETED | VRE Therapy and Alprazolam | 15 | |
| Overall Study | NOT COMPLETED | VRE Therapy and Placebo | 19 |
Source ClinicalTrials.gov
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals9
The totals the trial posted for each group.
| Total | Group | Affected | At risk |
|---|---|---|---|
| Total, all-cause mortality | VRE Therapy and D-cycloserine | ||
| Total, all-cause mortality | VRE Therapy and Alprazolam | ||
| Total, all-cause mortality | VRE Therapy and Placebo | ||
| Total, other adverse events | VRE Therapy and D-cycloserine | 0 | 53 |
| Total, other adverse events | VRE Therapy and Alprazolam | 0 | 50 |
| Total, other adverse events | VRE Therapy and Placebo | 0 | 53 |
| Total, serious adverse events | VRE Therapy and D-cycloserine | 0 | 53 |
| Total, serious adverse events | VRE Therapy and Alprazolam | 0 | 50 |
| Total, serious adverse events | VRE Therapy and Placebo | 0 | 53 |
Source ClinicalTrials.gov
Papers3
The papers the trial lists on ClinicalTrials.gov.
Grants1
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
| Project | Title | Principal investigators | Organization | Funder | Fiscal years |
|---|---|---|---|---|---|
| R01MH070880 | Cognitive Enhancer May Facilitate Behavioral Exposure | ROTHBAUM, BARBARA O | EMORY UNIVERSITY | NATIONAL INSTITUTE OF MENTAL HEALTH | 2005 to 2010 |
Source NIH RePORTER
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT00356278
GET https://conductscience.org/api/trials/v1/NCT00356278/results?page=2